REFERENCES
- Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92
- Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylcstradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233–42
- Lammers P, op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497–500
- Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988; 67: 171–4
- Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3: 179–89
- Archer DF, Maheux R, DelConte A, O'Brien FB, North American Levonorgestrel Study group. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®). Am J Obstet Gynecol 1999; 181: S39–44
- Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschinidt I, Heithecker R. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34
- Dusterberg B, Ellman H, Muller U, Rowe E, Muhe B. A 3-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10: 33–9
- Bannemerschult R, Hanker JP, Wünsch C, Fox P, Albring M, Brill K. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control and safety of a new low-dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles. Contraception 1997; 56: 285–90
- Loudon NB, Kirkman RJ, Dewsbury JA. A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. Eur J Obstet Gynecol Reprod Biol 1990; 34: 257–66
- Gestodene Study Group 324. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg and a 21-day regimen of desogestrel 150 μg and ethinylestradiol 20 μg. Eur J Contracept Reprod Health Care 1999; 4(Suppl 2): 17–25
- Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469–75
- Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring, and oral levonorgestrel/ethinylestradiol. Am J Obstet Gynecol 2002; 186: 389–95
- Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2): 19–24
- Szarewski A. High acceptability and satsifaction with NuvaRing use. Eur J Contracept Reprod Health Care 2002; 7(Suppl 2): 25–30